Mansi James A, Hensler Heather R, Dawson Rachel, Tuckson Reed, Wolynn Todd
Moderna, Inc., Cambridge, MA 02142, USA.
Black Coalition Against COVID, Atlanta, GA 30328, USA.
Vaccines (Basel). 2024 Sep 19;12(9):1072. doi: 10.3390/vaccines12091072.
The COVID-19 pandemic has had a significant impact on every individual in the United States. The launch of the COVID-19 vaccines is estimated to have averted millions of deaths and reduced over 18 million COVID-19-related hospitalizations. In September 2023, the updated 2023-2024 COVID-19 vaccine, which includes a monovalent component that corresponds to the omicron variant XBB.1.5, reflecting the predominant circulating variant at the time of strain selection, was approved and was recommended for use in all people ≥ 6 months of age. Despite this recommendation, the US uptake of the updated COVID-19 vaccines over the 2023-2024 season has been far from optimal, placing many people at unnecessary risk of severe COVID-19 outcomes. This paper provides an overview of the current state of COVID-19 in 2023-2024 and barriers to vaccine uptake. With the continued evolution of the virus, the potential for more virulent variants, reduced public acceptance of vaccination, and the potential barriers that contributed to low vaccine uptake are explored to provide solutions for improving COVID-19 protection for future seasons.
新冠疫情对美国的每一个人都产生了重大影响。据估计，新冠疫苗的推出避免了数百万例死亡，并减少了超过1800万例与新冠相关的住院病例。2023年9月，2023 - 2024年更新的新冠疫苗获得批准，该疫苗包含一种与奥密克戎变种XBB.1.5相对应的单价成分，这反映了毒株选择时主要流行的变种，并被建议用于所有6个月及以上的人群。尽管有此建议，但在2023 - 2024年期间，美国对更新后的新冠疫苗的接种情况远未达到最佳水平，使许多人面临不必要的严重新冠后果风险。本文概述了2023 - 2024年新冠疫情的现状以及疫苗接种的障碍。随着病毒的持续演变，探讨了出现更具毒性变种的可能性、公众对疫苗接种接受度降低的情况以及导致疫苗接种率低的潜在障碍，以为未来季节改善新冠防护提供解决方案。
